Yüklüyor......
Liver Transcriptomic Reveals Novel Pathways of Empagliflozin Associated With Type 2 Diabetic Rats
The hypoglycaemic target of empagliflozin (EMP), as a novel inhibitor of sodium-glucose cotransporter (SGLT2), is clear. However, recent studies have shown that EMP also has an important role in lipid metabolism and cardiovascular diseases. The liver plays an important role in the development of typ...
Kaydedildi:
| Yayımlandı: | Front Endocrinol (Lausanne) |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7092631/ https://ncbi.nlm.nih.gov/pubmed/32256445 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2020.00111 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|